genomewid
analysi
mode
action
potent
antivir
agent
led
identif
dihydroorot
dehydrogenas
dhodh
target
along
discoveri
knockdown
gene
pyrimidin
salvag
pathway
sensit
cell
ineffect
antivir
presenc
physiolog
uridin
concentr
explor
combin
pyrimidin
salvag
inhibitor
synthes
evalu
analog
cyclopentenyl
uracil
cpu
inhibitor
uridin
salvag
found
cpu
effici
convert
triphosph
cell
combin
led
larg
drop
cellular
utp
ctp
pool
consequ
suppress
dengu
viru
replic
presenc
physiolog
concentr
uridin
addit
combin
markedli
enhanc
effect
rnadepend
rna
polymeras
rdrp
inhibit
viral
genom
infect
find
highlight
new
hosttarget
strategi
potenti
antivir
activ
rdrp
inhibitor
signific
progress
develop
antivir
drug
come
target
viral
protein
small
molecul
jordheim
et
al
lou
et
al
exampl
compound
like
aciclovir
zidovudin
block
viral
revers
transcriptas
treat
herp
simplex
viru
hiv
infect
respect
rnadepend
rna
polymeras
rdrp
inhibitor
like
dasabuvir
sofosbuvir
use
treat
hepat
c
viru
infect
et
al
recent
broadspectrum
rdrp
inhibitor
remdesivir
gordon
et
al
enter
clinic
trial
coronaviru
diseas
meanwhil
target
host
protein
requir
viral
propag
emerg
attract
altern
may
circumv
emerg
resist
bekerman
einav
exampl
maraviroc
inhibit
human
chemokin
receptor
therefor
use
treat
multidrugresist
hiv
liebermanblum
et
al
addit
pyrimidin
biosynthesi
emerg
potenti
hosttarget
strategi
antivir
okesli
et
al
focu
devis
hosttarget
antivir
approach
treatment
rna
virus
caus
mani
seriou
diseas
hepat
influenza
ebola
dengu
mammalian
cell
pyrimidin
biosynthesi
tightli
regul
metabol
process
two
complementari
pathway
de
novo
biosynthesi
pyrimidin
salvag
respons
produc
utp
ctp
host
well
viral
rna
synthesi
figur
de
novo
pyrimidin
biosynthesi
resourceintens
process
contrast
salvag
occur
via
phosphoryl
ump
cmp
deriv
intracellular
rna
degrad
via
facilit
transport
phosphoryl
extracellular
uridin
whose
plasma
concentr
tightli
control
low
micromolar
rang
traut
recent
discov
broadspectrum
antivir
agent
first
report
harvey
et
al
potent
inhibitor
dihydroorot
dehydrogenas
dhodh
ratelimit
step
de
novo
pyrimidin
biosynthesi
dean
et
al
cours
unbias
genomewid
studi
also
found
knockdown
uridinecytidin
kinas
cytidin
monophosph
kinas
pyrimidin
salvag
pathway
strongli
sensit
cell
growth
inhibit
dean
et
al
find
consist
observ
often
lack
antivir
efficaci
vivo
despit
high
potenc
vitro
presum
due
salvag
metabol
circul
uridin
virusinfect
cell
traut
wang
et
al
restor
antivir
efficaci
presenc
extracellular
uridin
therefor
sought
inhibit
pyrimidin
salvag
cyclopentenyl
uridin
cpu
carbocycl
analogu
uridin
shown
inhibit
human
lim
et
al
surpris
learn
antivir
activ
cpu
due
remark
abil
deplet
intracellular
pyrimidin
nucleotid
pool
via
salvag
biosynthesi
pathway
find
led
us
redirect
search
fundament
new
type
combin
chemotherapi
rna
virus
describ
synthesi
dhodh
inhibitor
gene
sensit
cell
highlight
yellow
box
reaction
shown
blue
arrow
compris
de
novo
biosynthet
pathway
wherea
red
arrow
compris
salvag
pathway
search
lead
inhibitor
pyrimidin
salvag
inspir
earlier
report
biolog
activ
cpu
cyclopentenyl
cytosin
cpc
shown
block
uridin
salvag
vitro
vivo
cysyk
et
al
lim
et
al
moyer
et
al
schimmel
et
al
report
cpu
found
remark
welltoler
wherea
cpc
consider
cytotox
blaney
et
al
ford
et
al
song
et
al
contrast
like
due
downstream
inhibit
ctp
synthetas
cpc
schimmel
et
al
due
high
toxic
cpc
undertook
structureact
relationship
sar
analysi
cpu
wherein
uracil
nucleobas
maintain
intact
modifi
posit
meanwhil
substitu
cpu
modifi
site
phosphoryl
order
rapidli
access
nucleobas
carbocycl
moieti
analog
implement
diversityori
synthet
approach
featur
mitsunobu
reaction
strateg
transform
choi
et
al
first
synthes
cpu
analog
nucleobas
modif
figur
mitsunobu
reaction
common
cyclopentenyl
moieti
choi
et
al
benzoyl
protect
uracil
c
fluorouracil
c
iodouracil
thymin
racin
et
al
furnish
carbon
skeleton
analog
remov
acet
benzoyl
tbdp
group
deliv
analog
next
turn
synthesi
cpu
analog
modifi
posit
cyclopentenyl
moieti
figur
select
deprotect
tbdp
tbaf
reveal
primari
hydroxyl
group
song
et
al
methyl
presenc
cosm
g
francisco
et
al
afford
protect
altern
alcohol
could
convert
termin
fluorid
diethylamino
sulfurotrifluorid
dast
result
protect
cpu
mesyl
acetyl
follow
substitut
schaudt
blechert
pd
oh
catalyz
hydrogen
bianco
et
al
afford
protect
respect
result
protect
intermedi
treat
methanol
ammonia
andor
hcl
provid
analog
mei
aceton
f
dast
g
mscl
h
dmf
accl
j
pd
oh
cyclohexen
ethanol
tbdpstertbutyldiphenyl
silyl
bzbenzoyl
tbaftetranbutylammonium
fluorid
dastdiethylaminosulfur
trifluorid
ms
methanesulfonyl
acacetyl
order
guid
sar
studi
develop
enzymat
assay
evalu
inhibitori
effect
cpu
analog
recombin
human
express
purifi
e
coli
continu
assay
system
optim
coupl
activ
pyruv
kinas
pk
reaction
turn
coupl
lactat
dehydrogenas
ldh
tomoik
et
al
overal
reaction
progress
continu
monitor
detect
uv
absorpt
chang
nm
correl
atp
consumpt
effect
cpu
analog
activ
evalu
presenc
uridin
cpu
show
much
higher
atp
consumpt
compar
analog
figur
suggest
two
compound
substrat
individu
measur
steadi
state
kinet
paramet
use
uridin
cpu
substrat
km
valu
kcat
km
valu
figur
predict
rel
magnitud
kinet
paramet
addit
cpu
assay
mixtur
contain
uridin
atp
result
dosedepend
decreas
rate
ump
synthesi
figur
cpu
substrat
identifi
panel
carbocycl
nucleosid
analog
agent
measur
inhibitori
activ
enzym
figur
ki
valu
two
potent
competit
inhibitor
respect
figur
given
cpu
could
phosphoryl
sought
establish
whether
correspond
monophosph
substrat
human
purpos
human
express
e
coli
purifi
employ
recombin
synthes
cmp
cpump
confirm
ident
lcmsm
figur
result
shown
figur
demonstr
cpump
substrat
former
better
substrat
ident
correspond
product
cpudp
also
confirm
lcmsm
figur
understand
metabol
implic
biochem
find
develop
lcmsm
base
assay
facilit
measur
effect
intracellular
pyrimidin
nucleotid
level
minim
perturb
effect
sampl
quench
analysi
physiolog
concentr
metabolit
adapt
earlier
protocol
grow
cell
glass
cover
slip
facilit
rapid
wash
figur
martano
et
al
lcm
nucleotid
tabl
msm
transit
select
precursor
perform
use
dynam
multipl
reaction
monitor
dmrm
method
sartain
et
al
addit
micromolar
concentr
medron
acid
mobil
phase
markedli
increas
sensit
detect
diand
trinucleotid
method
hsiao
et
al
copyright
holder
preprint
peerreview
http
optim
sampl
analysi
method
hand
pyrimidin
nucleotid
level
measur
cell
cultur
either
cpu
combin
uridin
h
figur
inclus
cpu
led
larg
decreas
utp
ctp
level
compar
cell
treat
alon
effect
grew
pronounc
h
figur
cpu
deplet
utp
ctp
concentr
strongli
triphosph
cpu
could
detect
lcm
figur
suggest
nucleosid
diphosph
kinas
mammalian
enzym
known
broad
substrat
scope
lascu
gonin
could
convert
cpudp
correspond
nucleosid
triphosph
analog
inclus
cpu
also
led
moder
decreas
ump
cmp
udp
cdp
level
compar
cell
treat
alon
h
h
figur
despit
inhibitori
activ
vitro
deplet
intracellular
nucleotid
level
even
appear
increas
level
intracellular
nucleotid
figur
figur
contrast
suggest
activ
cpu
deriv
primarili
flux
pyrimidin
metabol
pathway
inhibit
assay
cultur
medium
supplement
uridin
error
bar
repres
sd
three
biolog
replic
statist
comparison
untreat
control
provid
utp
level
blue
ctp
level
red
signific
ns
p
p
p
p
calcul
one
way
anova
dunnett
test
b
lcm
detect
mono
diand
triphosph
cpu
cell
enzymolog
metabol
data
hypothes
combin
cpu
would
effect
inhibit
dengu
viru
replic
combin
use
infecti
clone
dengu
serotyp
strain
engin
express
luciferas
report
dean
et
al
hierholz
killington
marceau
et
al
efficaci
cytotox
combin
treatment
test
infect
uninfect
cultur
lung
carcinoma
cell
line
figur
assay
cultur
medium
supplement
uridin
mimic
physiolog
plasma
concentr
presenc
exogen
uridin
de
novo
pyrimidin
synthesi
inhibitor
alon
significantli
inhibit
viral
infect
cellular
viabil
figur
line
origin
hypothesi
combin
either
cpu
caus
signific
reduct
viral
infect
unlik
cyclopentenyl
compound
test
figur
howev
cpu
appear
workabl
therapeut
index
concentr
time
point
copyright
holder
preprint
peerreview
http
examin
efficaci
cytotox
cpu
conduct
comprehens
checkerboard
analysi
combin
neither
cpu
effect
singl
agent
physiolog
uridin
level
combin
molecul
success
suppress
dengu
viru
infect
figur
exampl
combin
cpu
inhibit
viru
replic
figur
cpu
dose
mm
viru
replic
suppress
almost
complet
notabl
combin
treatment
much
less
effect
cell
growth
suggest
combin
cpu
could
select
inhibit
viru
host
replic
demonstr
intracellular
nucleotid
deplet
correl
antivir
activ
also
test
effect
combin
broad
inhibitor
nucleosid
transport
dipyridamol
dpi
drug
significantli
suppress
intracellular
nucleotid
level
figur
consequ
inhibit
viral
replic
figur
given
combin
abl
select
inhibit
viral
infect
modul
intracellular
nucleotid
pool
hypothes
combin
potenti
effect
rdrp
inhibitor
viral
genom
replic
among
rdrp
inhibitor
nucleosid
inhibitor
ni
class
largest
klumpp
et
al
progress
furthest
studi
dengu
viru
lim
et
al
mani
ni
nucleosid
analog
reli
intracellular
phosphoryl
form
triphosph
substrat
block
rdrp
sofia
et
al
exampl
cytidin
analogu
prodrug
balapiravir
assess
treat
hcv
later
dengu
viru
infect
chen
et
al
klumpp
et
al
howev
balapiravir
fail
clinic
trial
dengu
due
limit
efficaci
nguyen
et
al
test
whether
combin
therapi
approach
could
improv
efficaci
treat
cell
combin
cpu
expect
show
dosedepend
inhibit
dengu
viru
replic
figur
inhibit
either
de
novo
salvag
pyrimidin
biosynthesi
alon
potenti
antivir
activ
caus
addit
cytotox
figur
contrast
inhibit
de
novo
salvag
pathway
markedli
enhanc
potenc
figur
presenc
cpu
lower
notabl
regimen
minim
impact
cytotox
profil
figur
regard
analogu
abl
slightli
potenti
antivir
activ
wherea
appear
actual
decreas
antivir
efficaci
figur
robust
intracellular
phosphoryl
critic
cpu
activ
confirm
competit
two
compound
intracellular
kinas
ratelimit
monophosphoryl
step
ford
et
al
klumpp
et
al
minim
despit
group
known
sole
phosphoryl
deoxycytidin
kinas
dck
klumpp
et
al
inde
substrat
hand
figur
similarli
cyclopentenyl
compound
substrat
dck
ford
et
al
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
gain
insight
mechan
underli
improv
efficaci
cpu
deploy
replicon
assay
bypass
viral
entri
electropor
denv
rna
alvarez
et
al
marceau
et
al
replicon
system
includ
code
region
need
viral
rna
translat
replic
lack
structur
gene
necessari
product
viral
particl
consequ
viral
genom
replic
examin
independ
viral
entri
particl
assembl
kato
hishiki
assay
figur
alon
inhibit
de
novo
pyrimidin
biosynthesi
alon
alter
valu
wherea
addit
cpu
shift
target
de
novo
salvag
pathway
combin
gsk
cpu
lower
result
suggest
intracellular
nucleotid
deplet
major
driver
cpu
antivir
activ
togeth
find
highlight
potenti
combin
modul
pyrimidin
metabol
inhibitor
viral
genom
replic
flavivirus
includ
dengu
viru
import
class
clinicallyrelev
viral
pathogen
limit
treatment
option
boldescu
et
al
particular
dengu
caus
hundr
million
symptomat
infect
annual
yet
lack
antivir
treatment
sole
approv
vaccin
limit
use
safeti
risk
associ
vaccin
individu
previous
expos
dengu
lim
et
al
sridhar
et
al
seri
highthroughput
phenotyp
cellbas
screen
recent
identifi
dhodh
inhibit
potent
broadspectrum
antivir
strategi
vitro
hoffmann
et
al
lucashourani
et
al
luthra
et
al
wang
et
al
furthermor
dhodh
inhibitor
recent
shown
suppress
vitro
xiong
et
al
howev
dhodh
inhibitor
often
lose
antivir
activ
upon
extracellular
uridin
addit
due
presum
pyrimidin
salvag
dean
et
al
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
examin
viral
replic
combin
rdrp
inhibitor
treatment
luminesc
denv
replicon
rna
express
luciferas
cell
h
assay
cultur
medium
supplement
uridin
error
bar
repres
sd
three
replic
prior
studi
explor
combin
dhodh
inhibitor
guanosin
analog
ribavirin
nonuridin
supplement
cell
cultur
dengu
model
yeo
et
al
antivir
efficaci
dhodh
salvag
inhibitor
previous
report
despit
interest
luthra
et
al
herein
found
combin
treatment
effect
block
dengu
viru
replic
presenc
physiolog
concentr
extracellular
uridin
time
deplet
utp
ctp
led
synergi
combin
rdrp
inhibit
synthesi
evalu
seri
cpu
analog
reveal
cpu
substrat
result
monophosph
substrat
combin
flux
cpu
triphosph
form
deplet
intracellular
pool
pyrimidin
ntp
figur
nonsubstr
analogu
deplet
intracellular
pyrimidin
despit
vitro
inhibitori
activ
result
suggest
cpu
activ
host
cell
driven
abil
block
multipl
target
pyrimidin
salvag
rather
sole
inhibit
distinct
antivir
activ
cpu
could
conceiv
origin
hosttarget
modul
pyrimidin
metabol
well
potenti
direct
act
antivir
activ
triphosph
viral
replic
intracellular
nucleotid
deplet
appear
correl
antivir
activ
given
structur
unrel
nucleosid
transport
inhibitor
dpi
also
suppress
intracellular
nucleotid
level
viral
replic
figur
addit
cpu
absenc
slightli
potenti
effect
viral
replic
figur
translat
decreas
viral
infect
time
point
figur
nevertheless
investig
inhibitori
effect
cputp
dengu
rdrp
warrant
inde
note
previous
ni
largest
class
rdrp
inhibitor
klumpp
et
al
addit
multifactori
approach
incorpor
inform
interact
multipl
host
viral
enzym
like
use
futur
sar
around
cpu
compound
remain
efficaci
panel
cpu
known
safe
vitro
blaney
et
al
ford
et
al
song
et
al
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
show
appreci
toxic
mice
cysyk
et
al
nonhuman
primat
blaney
et
al
safeti
profil
remain
less
clear
dhodh
inhibitor
like
teriflunomid
brequinar
extens
studi
human
gener
welltoler
ali
et
al
meanwhil
mani
rdrp
inhibitor
evalu
clinic
trial
dengu
preliminari
studi
combin
cpu
de
novo
synthesi
inhibitor
vivo
result
toxic
cysyk
et
al
preced
combin
inhibitor
de
novo
pyrimidin
synthesi
nucleosid
transport
inhibitor
human
casper
et
al
care
dose
optim
result
suggest
combin
strategi
target
host
pyrimidin
biosynthesi
viral
rdrp
hold
promis
potenti
therapi
rna
virus
light
grow
interest
rdrp
dhodh
inhibitor
antivir
agent
find
shine
light
promis
way
enhanc
clinic
util
combin
modul
mammalian
pyrimidin
metabol
author
wish
thank
roberto
mateo
david
constant
khanh
nguyen
help
discuss
technic
advic
research
support
grant
nation
institut
health
nation
institut
allergi
infecti
diseas
ck
mb
jc
also
jc
acknowledg
nih
financi
support
ag
support
nation
scienc
foundat
graduat
research
fellowship
stanford
chemh
chemistrybiolog
interfac
predoctor
train
program
fellowship
ql
ag
ck
design
research
ql
ag
wq
perform
research
ql
ag
ao
cf
ms
jc
mb
ck
analyz
data
ql
ag
ck
wrote
paper
cell
line
maintain
humidifi
incub
cell
obtain
atcc
cultur
dmem
supplement
fb
penicillinstreptomycin
lglutamin
upon
reach
confluenc
cell
detach
growth
surfac
use
trypsinedta
solut
prior
analysi
cell
maintain
logarithm
growth
biolog
assay
design
pdenvluc
infecti
clone
deriv
dengu
serotyp
strain
describ
detail
marceau
et
al
marceau
et
al
plasmid
linear
xbai
vitro
transcrib
genom
rna
denvluc
viru
use
megascript
kit
ambion
presenc
ppp
g
rna
cap
structur
analog
neb
denvluc
rna
electropor
vero
cell
transfect
cell
resuspend
dulbecco
modifi
eagl
medium
dmem
invitrogen
fb
uml
penicillinstreptomycin
transfer
flask
incub
supernat
collect
replenish
fresh
medium
everi
h
day
posttransfect
pool
togeth
clarifi
centrifug
store
aliquot
amount
infecti
denvluc
viru
stock
titrat
use
assay
calcul
spearman
algorithm
describ
previous
hierholz
killington
plasmid
pdenvluc
replicon
contain
renilla
luciferas
express
denv
subgenom
replicon
describ
previous
marceau
et
al
vitro
transcript
ug
plasmid
dna
linear
use
xbai
restrict
enzym
replicon
rna
gener
use
megascript
transcript
kit
presenc
ppp
g
rna
cap
structur
analogu
two
million
cell
wash
twice
pb
resuspend
electropor
buffer
teknova
mix
ug
purifi
replicon
rna
electropor
use
biorad
gene
pulser
xcell
electropor
use
squar
wave
protocol
electropor
cell
resuspend
prewarm
cultur
medium
without
antibiot
seed
requir
luciferas
express
measur
use
renilla
luciferas
assay
system
promega
follow
manufactur
instruct
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
unless
otherwis
note
reaction
perform
argon
atmospher
flameor
ovendri
glasswar
reaction
mixtur
stir
use
teflonco
magnet
stirrer
bar
monitor
thin
layer
silica
gel
chromatographi
tlc
use
mm
silica
gel
plate
fluoresc
indic
merck
plate
visual
uv
treat
stain
gentl
heat
product
purifi
analogix
intelliflash
flash
column
chromatographi
system
use
solvent
gradient
indic
anhydr
tetrahydrofuran
thf
dichloromethan
dimethylformamid
dmf
aceton
dimethyl
sufoxid
dmso
obtain
acro
organ
diethyl
ether
ethyl
acet
etoac
hexan
methanol
meoh
fisher
scientif
dmso
use
bioassay
prepar
biolog
sampl
fisher
bioreag
reagent
commerci
supplier
use
receiv
without
addit
purif
sampl
prepar
biolog
evalu
purifi
via
prepar
hplc
wateracetonitril
mecn
gradient
contain
vv
trifluoracet
acid
tfa
use
agil
infin
system
equip
agil
column
x
mm
nmr
spectra
measur
varian
inova
h
mhz
c
mhz
varian
h
mhz
c
mhz
varian
inova
mhz
h
mhz
c
mhz
magnet
reson
spectromet
note
h
chemic
shift
report
rel
residu
solvent
peak
ppm
meod
ppm
follow
chemic
shift
multipl
singlet
brsbroad
singlet
doublet
triplet
q
quartet
dd
doublet
doublet
multiplet
coupl
constant
hz
integr
c
chemic
shift
report
rel
residu
deuter
solvent
c
signal
ppm
meod
ppm
round
one
decim
place
infrar
spectra
record
nicolet
ftir
spectromet
stanford
nano
share
facil
report
wavenumb
cm
optic
rotat
data
obtain
use
jasco
dip
report
c
ml
solvent
indic
sodium
line
nm
high
resolut
mass
spectra
obtain
agil
qtof
mass
spectromet
metabol
chemistri
analysi
center
stanford
univers
compound
prepar
step
dribos
accord
literatur
procedur
choi
et
al
suspens
mg
mmol
equiv
mg
mmol
equiv
mg
mmol
equiv
thf
ml
ad
dead
solut
toluen
equiv
w
toluen
addit
dead
reaction
mixtur
turn
white
suspens
yellow
solut
slowli
warm
room
temperatur
stir
overnight
reaction
mixtur
concentr
load
onto
flash
cartridg
purifi
linear
gradient
etoac
hexan
afford
mg
mmol
white
powder
c
meoh
ir
film
cm
compound
mg
mmol
ad
ml
solut
methanol
h
reaction
solvent
remov
posit
atmospher
result
solid
dri
high
vacuum
reaction
crude
treat
hcl
thf
stir
overnight
excess
ad
neutral
reaction
follow
addit
ml
meoh
result
suspens
filter
short
celit
pad
rins
meoh
concentr
result
crude
resuspend
ml
subject
hplc
purif
linear
gradient
mecn
tfa
tfa
prep
column
agil
mm
fraction
contain
desir
product
combin
lyophil
afford
final
product
mg
mmol
white
powder
similar
manner
compound
mg
mmol
equiv
react
mg
mmol
equiv
afford
intermedi
white
powder
mg
mmol
intermedi
mg
mmol
deprotect
afford
mg
mmol
white
powder
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
c
ir
film
cm
h
nmr
mhz
j
hz
br
br
j
hz
dd
j
hz
c
nmr
mhz
similar
manner
compound
mg
mmol
equiv
react
mmol
equiv
afford
intermedi
mg
white
powder
intermedi
mg
mmol
deprotect
afford
mg
mmol
white
powder
similar
manner
compound
mg
mmol
equiv
react
mg
mmol
equiv
afford
intermedi
white
powder
mg
mmol
intermedi
mg
mmol
deprotect
afford
mg
mmol
white
powder
c
ir
film
cm
c
meoh
ir
film
cm
h
nmr
mhz
meod
j
hz
q
j
hz
br
j
hz
q
j
hz
j
hz
j
hz
c
nmr
mhz
meod
hrm
esi
mz
mna
calcd
hydroxymethyl
solut
mg
mmol
equiv
thf
ml
ad
tbaf
mmol
equiv
thf
h
reaction
mixtur
quench
ml
satur
solut
extract
ml
etoac
combin
organ
layer
dri
anhydr
concentr
load
onto
g
flash
cartridg
purifi
linear
gradient
etoac
hexan
afford
free
primari
alcohol
mg
mmol
white
powder
copyright
holder
preprint
peerreview
http
doi
doi
biorxiv
preprint
hz
c
nmr
mhz
solut
mg
mmol
equiv
dri
aceton
ml
ad
mg
mmol
equiv
mei
mmol
equiv
reaction
mixtur
stir
room
temperatur
h
filter
celit
pad
concentr
vacuo
afford
residu
oil
mg
similar
manner
synthesi
crude
treat
ml
methanol
follow
hcl
thf
furnish
analog
mg
mmol
three
step
fluoromethyl
dion
alcohol
mg
mmol
equiv
ml
ad
stock
solut
dast
mmol
equiv
prepar
dilut
dast
ml
reaction
mixtur
warm
room
temperatur
stir
overnight
quench
ml
satur
result
mixtur
extract
ml
etoac
combin
organ
layer
dri
anhydr
concentr
load
onto
g
flash
cartridg
purifi
linear
gradient
etoac
hexan
afford
intermedi
mg
j
hz
similar
manner
synthesi
compound
mg
mmol
equiv
treat
ml
methanol
follow
hcl
thf
furnish
analog
mg
mmol
two
step
white
powder
solut
mmol
equiv
anhydr
ml
ad
mmol
equiv
follow
dropwis
addit
ml
mscl
stock
solut
mmol
equiv
stock
solut
prepar
dilut
ml
mscl
ml
min
reaction
mixtur
quench
ml
satur
aqueou
solut
extract
ml
dri
anhydr
concentr
load
flash
cartridg
purifi
linear
gradient
etoac
hexan
afford
compound
mg
mmol
pale
yellow
oil
c
ir
film
cm
azidomethyl
mesyl
intermedi
mg
mmol
equiv
ad
dmf
ml
mg
mmol
equiv
result
suspens
heat
stir
hour
follow
addit
ml
satur
solut
organ
layer
extract
wash
brine
concentr
reduc
pressur
crude
materi
purifi
flash
cartridg
linear
gradient
etoac
hexan
afford
azid
intermedi
mg
mmol
brown
oil
c
ir
film
cm
h
nmr
mhz
br
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
j
hz
j
hz
br
br
j
hz
j
hz
j
hz
j
hz
c
nmr
mhz
hrm
esi
mz
mh
calcd
intermedi
mg
mmol
equiv
ad
thf
concentr
hcl
reaction
mixtur
stir
room
temperatur
h
excess
amount
ad
neutral
reaction
follow
addit
ml
meoh
result
suspens
filter
short
celit
pad
rins
meoh
concentr
result
crude
resuspend
ml
subject
hplc
purif
linear
gradient
mecn
tfa
tfa
prep
column
agil
mm
fraction
contain
desir
product
combin
lyophil
afford
final
product
mg
mmol
white
powder
c
meoh
ir
film
cm
br
h
nmr
mhz
meod
j
hz
dd
j
hz
j
hz
j
hz
c
nmr
mhz
meod
yl
methyl
acet
triethylamin
ul
equiv
acetyl
chlorid
accl
mmol
equiv
sequenti
ad
solut
mg
mmol
equiv
ml
reaction
mixtur
warm
room
temperatur
stir
anoth
hour
satur
solut
ml
ad
organ
layer
extract
wash
concentr
reduc
pressur
crude
materi
purifi
flash
cartridg
linear
gradient
etoac
hexan
afford
intermedi
mg
mmol
colorless
oil
c
ir
film
cm
hrm
esi
mz
mh
calcd
solut
allyl
acet
mg
mmol
equiv
ethanol
ml
cyclohexen
ml
ad
w
pd
oh
carbon
catalyst
substrat
weight
result
suspens
stir
reflux
overnight
reaction
mixtur
filter
concentr
dri
high
vacuum
afford
mg
crude
materi
paleyellow
oil
similar
manner
prepar
mg
crude
product
treat
hcl
thf
afford
final
product
mg
mmol
two
step
white
solid
c
meoh
ir
film
cm
br
h
nmr
mhz
meod
j
hz
j
hz
j
hz
dd
j
hz
c
nmr
mhz
meoh
uridin
cytidin
kinas
clone
vector
use
ndei
noti
restrict
site
result
ctermin
result
plasmid
transform
e
coli
cell
electropor
recov
soc
h
plate
onto
lb
agar
plate
carbenicillin
overnight
c
singl
isol
coloni
inocul
ml
lb
supplement
carbenicillin
grown
shake
h
next
day
cell
use
inocul
l
autoclav
lb
carbenicillin
flask
shaken
optic
densiti
reach
protein
express
induc
mm
isopropyl
iptg
temperatur
chang
flask
shaken
addit
h
cell
pellet
collect
spin
media
rpm
min
pellet
obtain
frozen
liquid
nitrogen
store
protein
purif
cell
pellet
thaw
resuspend
lysi
buffer
contain
tri
mm
ph
nacl
mm
imidazol
mm
dtt
mm
cell
lyse
sonic
centrifug
h
supernat
incub
slurri
ninta
resin
load
onto
column
nickel
column
wash
buffer
tri
mm
ph
nacl
mm
dtt
mm
wash
step
contain
increas
concentr
imidazol
mm
sdspage
confirm
protein
fraction
protein
purifi
use
fast
protein
liquid
chromatographi
fplc
use
buffer
mm
trishcl
ph
dithiothreitol
dtt
glycerol
elut
buffer
b
mm
trishcl
ph
dithiothreitol
dtt
glycerol
mm
nacl
chang
gradient
minut
buffer
b
fplc
eluent
contain
protein
concentr
use
amicon
centrifug
filter
k
cutoff
enzym
store
storag
buffer
mm
trishcl
ph
glycerol
human
cytidin
monophosph
kinas
purifi
previous
describ
dean
et
al
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
continu
monitor
reaction
progress
spectrophotometr
atp
hydrolysi
coupl
nadh
oxid
via
pyruv
kinas
pk
lactat
dehydrogenas
ldh
tomoik
et
al
reaction
conduct
room
temperatur
plate
greiner
bioon
uvstar
half
area
mixtur
contain
mm
hepe
ph
mm
kcl
mm
atp
uridin
cpu
analog
nm
unless
otherwis
note
mm
phosphoenolpyruv
nadh
unitsml
pk
ldh
progress
monitor
linear
region
use
biotek
synergi
ht
kinet
inhibit
constant
determin
use
graphpad
prism
graphpad
softwar
reaction
conduct
room
temperatur
eppendorf
tube
mixtur
contain
mm
hepe
ph
mm
kcl
mm
mm
atp
mm
substrat
cytidin
cpu
gentli
mix
h
rock
shaker
reaction
mixtur
heat
minut
denatur
enzym
format
cpump
confirm
lcmsm
figur
similar
manner
assay
atp
hydrolysi
coupl
nadh
oxid
via
pyruv
kinas
pk
lactat
dehydrogenas
ldh
continu
monitor
reaction
progress
spectrophotometr
reaction
conduct
room
temperatur
plate
greiner
bioon
uvstar
half
area
mixtur
contain
mm
trishcl
ph
mm
kcl
mm
mm
dtt
nadh
mm
pep
unitsml
pk
ldh
reaction
mixtur
add
mm
stock
solut
substrat
cmp
commerci
vendor
denatur
reaction
mixtur
contain
newli
synthes
cmp
cpump
assay
buffer
mm
hepe
ph
mm
kcl
mm
uvreadout
nm
reach
stabl
ca
minut
mixtur
atp
assay
buffer
mm
trishcl
ph
mm
kcl
mm
mm
dtt
ad
give
final
reaction
volum
final
atp
concentr
nm
progress
monitor
linear
region
use
biotek
synergi
ht
kinet
constant
determin
use
graphpad
prism
graphpad
softwar
gener
cpudp
confirm
lcmsm
figur
cell
plate
overnight
cellswel
plate
complet
dmem
next
day
cell
treat
dipyridamol
cpu
dmem
addit
supplement
uridin
six
twelv
hour
drug
addit
cell
cultur
medium
remov
whole
plate
rapidli
rins
twice
dip
vertic
beaker
contain
milliq
water
plate
place
dri
ice
follow
addit
ml
lysi
buffer
mecn
meoh
contain
formic
acid
nm
uridin
monophosph
sodium
salt
sigma
aldrich
solut
sonic
minut
ice
metabolit
extract
subsequ
sampl
frozen
liquid
nitrogen
freezedri
resuspend
milliq
water
final
filter
multiscreen
filter
plate
prior
lcm
analysi
lcmsm
perform
agil
infin
ii
lc
system
tandem
tripl
quad
mass
spectromet
use
ion
pair
chromatographi
lc
separ
perform
solvent
flow
rate
mlmin
zorbax
rrhd
column
mm
buffer
contain
meoh
mm
tributylamin
mm
acet
acid
medron
acid
buffer
b
contain
ca
meoh
mm
tributylamin
mm
acet
acid
medron
acid
initi
mobil
phase
composit
solvent
gradient
b
sampl
inject
follow
min
min
min
min
min
autosampl
temperatur
set
sampl
inject
sampl
measur
neg
esi
mode
capillari
voltag
sourc
set
follow
ga
temperatur
ga
flow
lmin
nebul
psi
sheath
ga
temperatur
sheath
ga
flow
lmin
nozzl
voltag
v
delta
emv
acquisit
perform
dynam
multipl
reaction
monitor
dmrm
mode
fragment
pattern
retent
time
set
tabl
si
cell
plate
overnight
cellswel
plate
complet
dmem
incub
cell
treat
pyrimidin
de
novo
synthesi
inhibitor
andor
salvag
inhibitor
andor
dmem
supplement
uridin
four
hour
drug
addit
cell
infect
viru
moi
h
h
denvluc
replic
monitor
product
renilla
luciferas
measur
use
renillaglo
luciferas
assay
system
promega
accord
specif
manufactur
accompani
cell
viabil
assay
cell
seed
cellswel
plate
complet
dmem
incub
cell
treat
pyrimidin
de
novo
synthesi
inhibitor
andor
salvag
inhibitor
andor
dmem
supplement
uridin
follow
h
h
treatment
cell
viabil
monitor
via
atp
level
measur
use
celltiterglo
luciferas
assay
system
promega
accord
specif
manufactur
test
combin
figur
cell
plate
overnight
cellswel
plate
complet
dmem
incub
h
cell
treat
pyrimidin
de
novo
synthesi
andor
salvag
inhibitor
dmem
supplement
uridin
four
hour
drug
addit
cell
infect
viru
moi
h
denvluc
replic
monitor
product
renilla
luciferas
measur
use
renillaglo
luciferas
assay
system
promega
accord
specif
manufactur
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
test
combin
figur
accompani
cell
viabil
assay
cell
seed
plate
densiti
cellswel
incub
h
cell
treat
pyrimidin
de
novo
synthesi
andor
salvag
inhibitor
dmem
supplement
uridin
follow
treatment
cell
harvest
densiti
viabl
cell
determin
flow
cytometri
fscssc
use
bd
accuri
flow
cytomet
transfect
cell
plate
cellswel
plate
immedi
treat
andor
pyrimidin
de
novo
synthesi
inhibitor
andor
salvag
inhibitor
complet
dmem
medium
supplement
uridin
without
antibiot
marceau
et
al
fortyeight
hour
drug
treatment
cell
lyse
subject
renilla
luciferas
detect
measur
use
renillaglo
luciferas
assay
system
promega
accord
specif
manufactur
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
nucleosid
synthesi
antimicrob
agent
chemoth
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
analysi
intracellular
pyrimidin
pool
cell
upon
drug
addit
lcm
analysi
intracellular
pyrimidin
tp
dp
mp
pool
h
indic
drug
treatment
row
data
repeat
figur
b
lcm
analysi
intracellular
pyrimidin
tp
dp
mp
pool
h
indic
drug
treatment
assay
cell
cultur
medium
supplement
uridin
dipyridamol
dpi
nucleosid
transport
inhibitorwa
use
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
posit
control
bar
indic
mean
sd
n
dot
repres
individu
valu
statist
signific
comparison
untreat
control
indic
uridin
compound
blue
cytidin
compound
red
p
p
p
ns
p
use
oneway
anova
dunnett
test
dp
graph
red
line
indic
lower
limit
reliabl
linear
quantit
cdp
statist
test
carri
cdp
mani
sampl
fell
lloq
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
